NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $3.52 +0.21 (+6.34%) Closing price 10/2/2026 04:10 PM EasternExtended Trading$3.63 +0.11 (+3.13%) As of 10/2/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsOwnershipSEC FilingsShort Interest About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Armata Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.32▼$3.5550-Day Range$3.31▼$5.8452-Week Range$3.08▼$16.34Volume124,467 shsAverage Volume375,619 shsMarket Capitalization$130.87 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for serious bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria. Armata’s approach is intended to address drug-resistant infections while limiting disruption to beneficial bacteria. The company’s pipeline has included inhaled phage products designed to treat chronic respiratory infections caused by Pseudomonas aeruginosa, including infections associated with cystic fibrosis and other structural lung diseases. Armata has also developed phage-based candidates targeting Staphylococcus aureus infections, including serious systemic infections. Its work includes phage discovery, selection and engineering, formulation, and the clinical development of pathogen-specific treatments. Armata is based in Marina del Rey, California, and serves the biotechnology and healthcare markets through research and clinical development activities. The company was formerly known as Synthetic Biologics, Inc. and adopted the Armata Pharmaceuticals name as it concentrated its operations on bacteriophage therapeutics. Because its products remain in development, their availability and approved uses depend on the results of clinical trials and regulatory review.AI Generated. May Contain Errors. Read More Armata Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreARMP MarketRank™: Armata Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingArmata Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialArmata Pharmaceuticals has a consensus price target of $15.00, representing about 326.1% upside from its current price of $3.52.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from $0.50 to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Armata Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.72% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 8.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentArmata Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ARMP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Armata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARMP Stock News HeadlinesJonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)September 28, 2026 | theglobeandmail.comArmata Pharmaceuticals Receives Additional Non-Dilutive Funding To Support AP-SA02 Phase 3 DevelopmentSeptember 23, 2026 | marketscreener.comMLarry's Three-Step Strategy Revealed at The Dollar Trap SummitLarry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocurrencies involved. The approach takes about 10 minutes to get started, and you don't need to be an accredited investor to follow along.October 4 at 1:00 AM | Brownstone Research (Ad)Armata Gets $3.7M DoW Funding For AP-SA02 Phase 3 Development; Stock DownSeptember 23, 2026 | rttnews.comArmata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 DevelopmentSeptember 23, 2026 | prnewswire.comArmata Pharmaceuticals, Inc. Presents Data On Defined Genetic Diversity In AP-SA02 At ISSSI 2026September 22, 2026 | marketscreener.comMArmata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical IsolatesSeptember 21, 2026 | prnewswire.comArmata Wins FDA Breakthrough Therapy Designation For AP-SA02 In Complicated SAB; Stock UpSeptember 14, 2026 | rttnews.comSee More Headlines ARMP Stock Analysis - Frequently Asked Questions How have ARMP shares performed this year? Armata Pharmaceuticals' stock was trading at $6.28 on January 1st, 2026. Since then, ARMP stock has decreased by 43.9% and is now trading at $3.52. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) issued its earnings results on Wednesday, August, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.18. The business had revenue of $2.51 million for the quarter, compared to analysts' expectations of $0.40 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 12.24% and a negative net margin of 3,467.04%. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN). Company Calendar Last Earnings8/12/2026Today10/04/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 11 days, ARMP's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:ARMP CIK921114 Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees61Year FoundedN/APrice Target and Rating Average Price Target for Armata Pharmaceuticals$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+326.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E Ratio7.04 P/E GrowthN/ANet Income-$173.80 million Net Margins-3,467.04% Pretax Margin-3,467.04% Return on Equity-12.24% Return on Assets32.16% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$4.90 million Price / Sales26.71 Cash FlowN/A Price / Cash FlowN/A Book Value($6.00) per share Price / Book-0.59Miscellaneous Outstanding Shares37,180,000Free Float5,763,000Market Cap$130.87 million OptionableNot Optionable Beta1.40 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:ARMP) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredJP Morgan: SpaceX could unlock "the next phase of the space economy"In 2024, Dylan Jovine flagged an obscure space stock trading under $4 a share. It later climbed as high as $15...Behind the Markets | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredFree Stock: Economist calls it “the world’s most important machine.”Nvidia's most expensive chip component isn't made by Nvidia. Jeff Brown, former semiconductor executive, says ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARMP Stock Alerts